Payment overview · 2025
General Payments
$1,508.90
39 reported records · 20 companies
Healthcare provider profile · identity verified
Mayur C Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BURBANK, CA · NPI 1669451571
Verified facts
What the public records show
CMS Open Payments records show Mayur C Patel, MD received $1,508.90 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Opsumit, Trelegy Ellipta.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Opsumit by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $328.23 | 21.8% | 10 | 2025 |
| Galvanize Therapeutics, Inc | Unresolved — no canonical attribution shown | $288.50 | 19.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $146.26 | 9.7% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $143.91 | 9.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $102.42 | 6.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $89.98 | 6.0% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $50.61 | 3.4% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $48.91 | 3.2% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $42.22 | 2.8% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $38.28 | 2.5% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $31.97 | 2.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.78 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.60 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.22 | 1.7% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $24.69 | 1.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.12 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.00 | 1.3% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.61 | 1.3% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.69 | 1.2% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $13.90 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,508.90 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ALIYA SYSTEM Normalized: aliya system |
Device | Galvanize Therapeutics, Inc | $288.50 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $254.53 | 6 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $146.26 | 2 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $143.91 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $67.84 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $54.82 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $50.61 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $48.91 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $38.28 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $38.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $38.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $38.28 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $31.97 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Veklury Normalized: veklury |
Drug | Gilead Sciences, Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Venclexta Normalized: venclexta |
Biological | Genentech USA, Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $5.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 267 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 280 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
280 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
267 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 101 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 280 | 49 |
| Eliquis | Apixaban | 267 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 69 |
| Montelukast Sodium | Montelukast Sodium | 247 | 67 |
| Omeprazole | Omeprazole | 241 | 56 |
| Breo Ellipta | Fluticasone/Vilanterol | 234 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 222 | 64 |
| Losartan Potassium | Losartan Potassium | 219 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 203 | 73 |
| Furosemide | Furosemide | 202 | 51 |
| Lisinopril | Lisinopril | 186 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 41 |
| Simvastatin | Simvastatin | 175 | 44 |
| Gabapentin | Gabapentin | 164 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 39 |
| Metformin Hcl | Metformin Hcl | 161 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 43 |
| Methylprednisolone | Methylprednisolone | 121 | 84 |
| Donepezil Hcl | Donepezil Hcl | 118 | 21 |
| Carvedilol | Carvedilol | 113 | 26 |
| Alprazolam | Alprazolam | 105 | 20 |
| Azithromycin | Azithromycin | 98 | 77 |
| Levetiracetam | Levetiracetam | 96 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 28 |
| Sertraline Hcl | Sertraline Hcl | 91 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 17 |
| Potassium Chloride | Potassium Chloride | 85 | 15 |
| Tramadol Hcl | Tramadol Hcl | 81 | 20 |
| Trazodone Hcl | Trazodone Hcl | 79 | 20 |
| Spironolactone | Spironolactone | 77 | 15 |
| Allopurinol | Allopurinol | 76 | 17 |
| Meloxicam | Meloxicam | 73 | 24 |
| Valsartan | Valsartan | 71 | 21 |
| Alendronate Sodium | Alendronate Sodium | 70 | 23 |
| Azelastine Hcl | Azelastine Hcl | 70 | 32 |
| Symbicort | Budesonide/Formoterol Fumarate | 65 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 63 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 17 |
| Buspirone Hcl | Buspirone Hcl | 56 | 11 |
| Jardiance | Empagliflozin | 55 | 12 |
| Mirtazapine | Mirtazapine | 55 | 14 |
| Pregabalin | Pregabalin | 55 | 14 |
| Xarelto | Rivaroxaban | 55 | 12 |
| Farxiga | Dapagliflozin Propanediol | 54 | 14 |
| Divalproex Sodium | Divalproex Sodium | 52 | suppressed |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 16 |
| Glimepiride | Glimepiride | 51 | 11 |
| Finasteride | Finasteride | 50 | suppressed |
| Irbesartan | Irbesartan | 49 | suppressed |
| Linzess | Linaclotide | 49 | suppressed |
| Clonazepam | Clonazepam | 47 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 47 | suppressed |
| Bumetanide | Bumetanide | 46 | suppressed |
| Atenolol | Atenolol | 45 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 39 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 43 | suppressed |
| Prednisone | Prednisone | 43 | 23 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Diazepam | Diazepam | 34 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 16 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Lactulose | Lactulose | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | 14 |
| Baclofen | Baclofen | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 20 |
| Carisoprodol | Carisoprodol | 30 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 30 | 11 |
| Breyna | Budesonide/Formoterol Fumarate | 29 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 11 |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Fentanyl | Fentanyl | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Famotidine | Famotidine | 23 | 12 |
| Livalo | Pitavastatin Calcium | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Niacin Er | Niacin | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Nystatin | Nystatin | 20 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Meropenem | Meropenem | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Acetazolamide | Acetazolamide | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nateglinide | Nateglinide | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | 12 |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Dayvigo | Lemborexant | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Estazolam | Estazolam | 11 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Opsumit | Macitentan | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,508.90 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ALIYA SYSTEM, Arikayce, BREZTRI, CHARTIS CATHETER, Cologuard Collection Kit, DUPIXENT, ELIQUIS, FARAPULSE, FASENRA, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JARDIANCE, NUCALA, NUZYRA, OFEV, OPSUMIT, PULMONX CHARTIS TABLET CONSOLE, REXULTI, SMARTVEST, TEZSPIRE, TRELEGY ELLIPTA, Tecentriq, ULTOMIRIS, UPTRAVI, Veklury, Venclexta, WINREVAIR, YUPELRI, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error